- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04811794
Young Survivors at Kantonsspital Aarau, Switzerland
Young Survivors at Kantonsspital Aarau, Switzerland - A Standardized Assessment of Long-Term and Late-Onset Health Events in Survivors of Childhood and Adolescent Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Around 250-300 children and adolescents below the age of 21 years are newly diagnosed with cancer in Switzerland every year. Research led to remarkable progress in survival in the last decades. The 10-year survival rate in Switzerland is currently 87%. Previous research showed that, depending on the treatment exposure, a high proportion of these survivors suffer from chronic medical conditions, so called late effects.
Many studies on late effects in former childhood cancer patients are based on retrospective data. However, this type of study design has unavoidable limitations, such as missing data, different coding and grading of severity of late effects, and the assessment at different time points. Therefore, we need prospectively collected data, including severity coding in a standardized way, to overcome these limitations.
Objectives:
The overarching aim of "Young Survivors at Kantonsspital Aarau, Switzerland" is to assess late effects in childhood cancer survivors prospectively and in a standardized way. These data will contribute to the increasing knowledge on long-term outcomes and late effects in the future. This new knowledge is important in order to be able to adapt and improve long-term follow-up care. In the longer term, survivors will benefit from this extensive and prospective data collection.
Methods:
"Young Survivors at Kantonsspital Aarau" has a registry-like design. Data produced during regular follow-up visits are collected in a comprehensive database and in a standardized way. We collect all information generated prospectively from start of the study onwards and retrospectively until January 2016. From 2016 onward, all medical records are kept electronically. We classify and grade the severity of late effects according to the modified National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.03). The outcome variables correspond to results from risk-stratified organ examinations, which are performed according to the Children's Oncology Group guidelines v5.0. The exposure variables correspond to information from the patients' medical history, including detailed information on cancer diagnosis and treatment. The data will be analyzed in an exposure- or organ system-driven approach. We start recruitment with patients diagnosed and treated at the Kantonsspital Aarau. The design of the study allows the inclusion of other clinics in the future.
Research and significance:
Research on late effects of former childhood cancer patients often relies on retrospective data collection, which is associated with unpreventable limitations. "Young Survivors at Kantonsspital Aarau" overcomes these limitations and additionally grades the severity of late effects in a standardized way. This allows us to analyze changes in severity of late effects over time, within and between survivors. This information will increase our knowledge on late effects and contribute to long-term follow-up care.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Katrin Scheinemann, MD
- Phone Number: +41628384909
- Email: katrin.scheinemann@ksa.ch
Study Locations
-
-
-
Aarau, Switzerland
- Recruiting
- Division of Oncology - Hematology, Department of Pediatrics, Kantonsspital Aarau
-
Principal Investigator:
- Katrin Scheinemann, MD
-
Sub-Investigator:
- Maria Otth, MD
-
Contact:
- Katrin Scheinemann, MD
- Phone Number: +41628384909
- Email: katrin.scheinemann@ksa.ch
-
Sub-Investigator:
- Daniel Drozdov, MD
-
Sub-Investigator:
- Claudia Huegli, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Group A:
Children and adolescents who:
- have been treated for cancer in the Division of Oncology-Hematology, Department of Pediatrics, at the Kantonsspital Aarau,
- have been diagnosed at age 0-18 years,
- are still in regular follow-up care at the Kantonsspital Aarau,
- have finished cancer treatment and entered follow-up care, and
- signed informed consent
Group B:
Adolescents and adults who:
- fulfill the same inclusion criteria as Group A
- are not in regular follow-up care anymore
Exclusion Criteria:
Childhood Cancer Survivors who:
- are in a palliative situation or
- have not given consent for further use of medical data
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group A (largest part of the cohort)
Children, adolescents, and adults who are still in follow-up care (data are collected retrospectively until 2016 at the most)
|
Physical examination, diagnostic tests (e.g.
lung function test, echocardiography, audiometry), and laboratory tests (e.g.
kidney parameter, hormonal levels) depend on examined organ system.
Personal history on diagnosis, treatment, and socioeconomic factors
|
Group B (very small part of the cohort)
Children, adolescents, and adults who left follow-up care (data are collected retrospectively until 2016 at the most)
|
Physical examination, diagnostic tests (e.g.
lung function test, echocardiography, audiometry), and laboratory tests (e.g.
kidney parameter, hormonal levels) depend on examined organ system.
Personal history on diagnosis, treatment, and socioeconomic factors
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Test results to assess organ-specific late effects (example of cardiac health)
Time Frame: at recruitment or 2016 onwards, whichever comes first
|
Number of survivors with heart valve disorder, hypertension, left ventricular systolic dysfunction when at risk for cardiac late effects
|
at recruitment or 2016 onwards, whichever comes first
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Test results to assess organ-specific late effects (example of cardiac health)
Time Frame: annually from recruitment or 2016 onwards, whichever comes first
|
Number of survivors with heart valve disorder, hypertension, left ventricular systolic dysfunction etc. when at risk for cardiac late effects
|
annually from recruitment or 2016 onwards, whichever comes first
|
Sociodemographic and socioeconomic characteristics (e.g. age at clinical examination, gender, education or working situation, living situation)
Time Frame: annually from recruitment or 2016 onwards, whichever comes first
|
annually from recruitment or 2016 onwards, whichever comes first
|
|
Comorbidities (e.g. arterial hypertension, obesity) as risk factors for late effects
Time Frame: annually from recruitment or 2016 onwards, whichever comes first
|
annually from recruitment or 2016 onwards, whichever comes first
|
|
Diagnosis-related data (e.g. age at diagnosis, diagnosis, disease stage, treatment protocol)
Time Frame: at recruitment or 2016 onwards, whichever comes first
|
at recruitment or 2016 onwards, whichever comes first
|
|
Treatment-related data (e.g. cumulative doses of chemotherapy and radiotherapy, surgery, hematopoietic stem cell transplantation )
Time Frame: at recruitment or 2016 onwards, whichever comes first
|
at recruitment or 2016 onwards, whichever comes first
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- AO_2020-00012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Childhood Cancer
-
Australian & New Zealand Children's Haematology...Medical Research Future Fund; Minderoo Foundation; Children's Cancer Institute...RecruitingChildhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain TumorAustralia
-
Sydney Children's Hospitals NetworkGerman Cancer Research Center; Australian & New Zealand Children's Haematology... and other collaboratorsRecruitingChildhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain TumorAustralia
-
University of Colorado, DenverRecruitingCancer | Childhood CancerUnited States
-
Children's Hospital of PhiladelphiaCompletedCancer | Childhood CancerUnited States
-
Wake Forest University Health SciencesTerminated
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
Pernille BidstrupOdense University Hospital; Aarhus University Hospital; Aarhus University Hospital... and other collaboratorsCompleted
-
Emory UniversityNational Cancer Institute (NCI)Recruiting
-
Children's Cancer Group, ChinaShanghai Children's Medical Center; Shanghai Municipal Center for Disease Prevention...Recruiting
-
St. Jude Children's Research HospitalRecruiting
Clinical Trials on Physical examination, diagnostic tests, laboratory tests
-
University of BernRecruitingChildhood Cancer | Late EffectSwitzerland
-
Istanbul Medipol University HospitalRecruitingFemoro Acetabular ImpingementTurkey
-
University of Kansas Medical CenterRecruitingHypertension | Chronic Pain | Implanted Stimulation ElectrodesUnited States
-
Luis SantosCompleted
-
Polish Mother Memorial Hospital Research InstituteCompletedHeart Failure | Arterial HypertensionPoland
-
University of AarhusCompletedMyocardial Ischemia | Coronary Artery Disease | Atherosclerosis | Angina PectorisDenmark
-
University of Maryland, College ParkVanderbilt University; National Institute on Deafness and Other Communication...Enrolling by invitationAging | Hearing Loss | Hearing Loss, Sensorineural | Cochlear Hearing LossUnited States
-
Polish Mother Memorial Hospital Research InstituteRecruitingHeart Failure | Covid19Poland
-
KU LeuvenUnknownUrinary Tract Infections
-
Mayo ClinicDepartment of Health and Human ServicesCompleted